Fimasartan

ApprovedSmall molecule

Fimasartan is a small molecule that works as a Type-1 Angiotensin II Receptor Antagonist.[2] It is being used across 11 indications, with its most advanced program in Approved.[1]

Fimasartan is one of 275 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

274

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseUnknown

Left Ventricular HypertrophyActive, not recruiting

Essential HypertensionActive, not recruiting

HyperlipidemiaActive, not recruiting

Insulin SecretionActive, not recruiting

Aortic StenosisActive, not recruiting

Diastolic Heart FailureActive, not recruiting

Kidney DiseaseActive, not recruiting

HypertensionActive, not recruiting

Type 2 DiabetesActive, not recruiting

Cardiovascular DiseasePreclinical

Unknown

Left Ventricular HypertrophyPreclinical

Active, not recruiting

Essential HypertensionPhase 3

Active, not recruiting

HyperlipidemiaPhase 1

Active, not recruiting

Insulin SecretionPreclinical

Active, not recruiting

Aortic StenosisApproved

Active, not recruiting

Diastolic Heart FailureApproved

Active, not recruiting

Kidney DiseasePhase 1

Active, not recruiting

HypertensionPhase 3

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Fimasartan

Boryung Pharmaceutical Co., Ltd

Approved

1 2

Glargine

Eli Lilly

Preclinical

8 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 5

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 6

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1 7

Sglt2i

UUniversity of Chicago

Preclinical

2 8

Biasp 30

Novo Nordisk

Preclinical

1 9

Glucagon-Like Peptide-1 (GLP-1)

Novo Nordisk

Preclinical

1 10

BQ123

VVanderbilt University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Essential Hypertension10 trials

A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 2·NCT00922441·92 enrolled

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT03156842·138 enrolled

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT05930028·148 enrolled

Show 7 more trials

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT02166814·140 enrolled

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT03338426·133 enrolled

The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT01135212·290 enrolled

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 2·NCT01878201·75 enrolled

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT01672476·293 enrolled

Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension

Completed·SStendhal Americas, S.A.·Phase 3·NCT02466490·272 enrolled

Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 2·NCT00923611·182 enrolled

Clinical Trial4 trials

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT02920047·60 enrolled

Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT01671020·16 enrolled

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT02704702·36 enrolled

Show 1 more trial

A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 2·NCT02222480·103 enrolled

Atorvastatin3 trials

Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT02397590·36 enrolled

A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT02566187·99 enrolled

A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT00991705·28 enrolled

Interaction3 trials

To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT01921946·50 enrolled

A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT00938197·34 enrolled

Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT02397538·50 enrolled

Hypertension3 trials

Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT00922480·506 enrolled

Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension

Completed·RR-Pharm·Phase 3·NCT02248961·179 enrolled

Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd··NCT02022774·90 enrolled

20 more indications

Blood Pressure2 trials

Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 4·NCT01736488·25 enrolled

Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan

Unknown status·—·Phase 4·NCT02958631·40 enrolled

Tics2 trials

A Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT01007409·24 enrolled

To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT02205151·86 enrolled

Hepatic Impairment1 trial

A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT01146938·18 enrolled

ART1 trial

Fimasartan in the Senior Subjects

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT03246555·241 enrolled

Combination Therapy1 trial

A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT05878561·248 enrolled

Efficacy1 trial

Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 2·NCT00937651·81 enrolled

Left Ventricular Hypertrophy1 trial

Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG

Completed·SSeoul National University Bundang Hospital··NCT03219632·72 enrolled

Insulin Secretion1 trial

Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients

Completed·SSeoul National University Hospital·N/A·NCT02312375·46 enrolled

Oral1 trial

A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT00923533·34 enrolled

Aortic Stenosis1 trial

A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)

Unknown status·SSeoul National University Hospital·Phase 4·NCT01589380·100 enrolled

Ischemic stroke1 trial

Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol

Unknown status·—·Phase 4·NCT02403349·105 enrolled

Type 2 Diabetes1 trial

Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT05173025·42 enrolled

Coronary Disease1 trial

Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

Terminated·SSeung-Jung Park·Phase 4·NCT01384747·186 enrolled

Phase II1 trial

Fimasartan/Amlodipine Combination Phase III

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT02152306·143 enrolled

Elderly1 trial

Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT00937534·22 enrolled

Diastolic Heart Failure1 trial

A Trial of Fimasartan for Early Diastolic Heart Failure

Completed·—·Phase 4·NCT01691118·60 enrolled

HIE1 trial

Fimasartan Achieving SBP Target (FAST) Study

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 4·NCT02495324·369 enrolled

Efficacy and Safety1 trial

A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT01258673·263 enrolled

Renal Impairment1 trial

A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT01148368·16 enrolled

Statin1 trial

to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 1·NCT02205190·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 45 trial records for Fimasartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fimasartan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fimasartan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boryung Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Type-1 Angiotensin II Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boryung Pharmaceutical Co., Ltd

Fimasartan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Essential Hypertension10 trials

Clinical Trial4 trials

Atorvastatin3 trials

Interaction3 trials

Hypertension3 trials

Blood Pressure2 trials

Tics2 trials

Hepatic Impairment1 trial

ART1 trial

Combination Therapy1 trial

Efficacy1 trial

Left Ventricular Hypertrophy1 trial

Insulin Secretion1 trial

Oral1 trial

Aortic Stenosis1 trial

Ischemic stroke1 trial

Type 2 Diabetes1 trial

Coronary Disease1 trial

Phase II1 trial

Elderly1 trial

Diastolic Heart Failure1 trial

HIE1 trial

Efficacy and Safety1 trial

Renal Impairment1 trial

Statin1 trial

References

Drug Info

Quick Facts

Related News